Access Article Clinical Trials Decriminalization 
Cannabis Law Report
AUGUST 10, 2021
As psychedelic therapy trials approach FDA approval, researchers express the urgent need to ensure effectiveness and accessibility to communities of color. Madison Natarajan, MS. – August 5, 2021.
Canna Law Blog
NOVEMBER 27, 2021
In fact, Small Pharma has been conducting trials as reported by the BBC and expanded its clinical trial this past summer. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction. BREAKING: City of Seattle Decriminalizes Psychedelics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 31, 2022
In a previous article, we explored one potential current opportunity for entrepreneurs interested in psychedelics and mycelium— producing non-psychoactive mushroom supplements. These therapists will likely benefit from further decriminalization measures and may be able to transition to state-regulated systems as these go live.
SpeedWeed
JULY 6, 2021
By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”. The project also intends to advance research into how psychedelics can heal trauma and how to ensure equitable access to these therapies. View original article.
Cannabis Law Report
JULY 9, 2021
Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. The state of the law on psychedelic substances is in flux. have also passed “Right to Try” laws.
Veriheal
DECEMBER 21, 2022
Rescheduling cannabis and decriminalizing cannabis do not mean the same thing for federal legalization. Decriminalization refers to the relaxation of criminal penalties associated with personal cannabis use. While both options seem better than the current situation, they could actually make it more difficult to access.
Canna Law Blog
NOVEMBER 6, 2021
Despite overwhelming evidence that psilocybin is misclassified, this barrier restricts research, stifles competition and innovation, and inhibits access. But only if it is made affordable and accessible. Instead, qualifying evidence may come from adequate and well-controlled clinical trials. For two decades, U.S.
Expert insights. Personalized for you.
105 
Let's personalize your content